Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / PARK7

PARK7

Basics

Aliases:
This biomarker is also known as:
  • Oncogene DJ-1,
  • Parkinson disease (autosomal recessive, early onset) 7,
  • DJ1,
  • Protein DJ-1,
  • Parkinson disease protein 7,
  • DJ-1,

View in BioMuta

Description…

DJ-1, also known as PARK-7, belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death. DJ-1 is highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart and is detected at slightly lower levels in placenta and brain.

Attributes

QA State: Accepted
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Three
QA State: Under Review

Overview

Validation study was conducted to determine whether DJ-1 antigens are associated with autoantibodies in sera collected at the pre-symptomatic stage of lung cancer.

Performance Comment

Supporting Study Data

The following studies/protocols provide evidence supporting PARK7 indications for the Lung…

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 39.0 51.0 N/A N/A N/A
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 82.0 25.0 N/A N/A N/A
Decision Rule

No extra decision rule information available

Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Studies

No associated studies or protocols found.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html